PHT8: DEVELOPMENT OF A NEW SCORING OF THE WOMEN'S HEALTH QUESTIONNAIRE (WHQ)  by Girod, I et al.
Abstracts 103
PMT6
MONITORING THE GATEKEEPER: 
METHODOLOGIES FOR THE DEVELOPMENT 
OF PROCESS AND OUTCOME MEASURES 
FOR THE EVALUATION OF IRBS
Gold KF1,2
1Abt Associates, Bethesda, MD, USA; 2Georgetown University, 
Department of Biostatistics, Washington, DC, USA
OPRR’s suspension of Duke’s IRB and the HHS report,
“Institutional Review Boards: A Time for Reform”
makes clear that effectiveness of IRBs is at issue. Over-
burdened, without formal training or established moni-
toring mechanisms, IRBs are vulnerable to compromise
as protocol submissions skyrocket. Development meth-
odologies for measures of such a complex institution are
needed. OBJECTIVE: To establish a methodology for
constructing and evaluating measures assessing IRBs.
METHODS: Evaluation of institutional entities such as
work by NCQA is reviewed. IRBs are complex entities
comprised of levels of individuals acting on the IRB’s be-
half. Uses of Hierarchical Linear Models to understand
interrelationships among levels assists measure develop-
ment. Generalizability theory, a complex cousin of reli-
ability, provides estimation of the required number of IRB
members, protocol-submitting doctors and other partici-
pants within each institution as well as the number of
items necessary to obtain “reliable” measures. Multi-trait,
multi-method analyses are used to assess the convergent
and divergent properties of measures particularly of value
in the absence of a “gold standard”. RESULTS: Simu-
lated data show generalizability of measures are increased
with an increased number of participants assessed and/or
number of items used and varies based on the homogene-
ity of subjects within institutions. Multi-trait multi-method
analyses indicate that measures with the highest reliabil-
ity that are more highly correlated with alternative mea-
sures of the same domain and less correlated with mea-
sures of different domains are the best candidates for
measures in the absence of a “gold standard”. CON-
CLUSIONS: During the politicized process of determin-
ing the substance of IRB measures that are trying to meet
the needs of diverse stakeholders including patients, med-
ical institutions and pharmaceutical companies, meth-
odological research can assess measures focusing on sta-
tistical characteristics. This approach companions the
substantive process, providing a basis for divergent inter-
ests to make progress in establishing measures of IRBs.
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THE FRENCH HEALTH UTILITIES INDEX MARK 3
Le Galès C1, Buron C1, Costet N1, Rosman S1, Slama G2
1INSERM, Le Kremlin Bicetre, France; 2Service d’Endocrinologie 
et Maladies Metaboliques-diabetologiques Hôtel-Dieu, Paris, 
France
The Health Utilities Index is a generic multiattribute pref-
erence-based system for assessing health-related quality
of life, originally devised by Torrance et al. It is being
widely used in cost-effectiveness evaluations in North
America and in international multicentre studies but was
not available in France. Following cross-cultural adapta-
tion and validation of the HUI3 classification in the
French population, the purpose of this investigation was
to derive population weights for the French instrument.
In June 1999, we implemented a population (n  365)
preference survey. Respondants were randomly selected
by phone to be representative of the structure French
general population and face-to-face interviews were con-
ducted. Visual Analogue Scale (VAS) and Standard Gam-
ble (SG) were used to reveal preferences on a scale run-
ning from 1 (perfect health) to 0 (all, worst or death
depending on the interviewee’s decision). The 8 single-
attribute value functions were directly revealed as well
as the corner states values. Rating of particular multi-
attribute health states was also done using both VAS and
SG. Firstly, our survey demonstrates the feasability of
eliciting values and utilities in a French sample. Secondly,
analysis concludes that collected data permit 1) to fit
multi-attribute value and utility functions for many indi-
viduals and 2) to discuss the appropriateness of the mul-
tiplicative functional form. Results obtained at the per-
son-mean and person-median levels from the French
survey will be presented and discussed. Emphasis will be
placed on the influence of socio-demographic characteris-
tics of the interviewees on elicited preferences. The
French HUI3 scoring function will also be compared to
the Canadian one.
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DEVELOPMENT OF A NEW SCORING OF THE 
WOMEN’S HEALTH QUESTIONNAIRE (WHQ)
Girod I1, Keininger D2, de la Loge C1, Hunter M3
1Mapi Values, Lyon, France; 2Mapi Research Institute, Lyon, 
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INTRODUCTION: The Women’s Health Questionnaire
(WHQ) is often used in international studies to assess
Quality of Life (QoL) in women. The 37-item WHQ was
developed in UK English and investigates 9 domains.
This hypothesized structure is usually not verified by con-
struct validity analysis in the reported literature. The pur-
pose of the present research was to refine the structure of
the WHQ across a large international sample of patients. 
The scoring of the WHQ was reviewed using data from
different countries: UK, US, France, Germany, Italy, Po-
land. 1) evaluating the WHQ hypothesized structure in
pooled European data using exploratory factorial analy-
sis and multitrait analyses; 2) developing a revised struc-
ture; 3) checking the revised structure in UK data using
structure equation modeling; 4) refining the structure; 5)
applying the final model in all countries and validating its
psychometric properties. RESULTS: Six items were de-
leted from the initial scoring and eight items were re-
grouped into other dimensions. Items of the sexual be-
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havior and menstrual symptoms dimensions were excluded
because of conceptual issues. In the future, they will be
presented as optional modules. The analyses identified a
new structural model applicable to pre, peri and post-
menopausal women. The new WHQ is made of a 23-
item core questionnaire which investigates 6 domains:
anxiety/depressed mood, well-being, somatic symptoms,
memory/concentration, vasomotor symptoms, and sleep
problems. The cross-sectional psychometric properties of
the 23-item WHQ in each country were good and found
to be better than those obtained using the 37-item ver-
sion. CONCLUSIONS: At this stage, the 23-item WHQ
can be used in international trials to assess the impact of
condition, disease or treatment on emotional and physi-
cal well-being of women. Its reproducibility and respon-
siveness to change over time need to be documented.
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ASSESSING THE COST-EFFECTIVENESS RATIO 
OF A NEW ANTI-PLATELET AGENT: 
METHODOLOGIC ISSUES
Levy E1, Gabriel S2, Dinet J2, Carita P2
1Université Paris IX Dauphine, Paris, France; 2Health Economics 
& Outcome Research Department, Sanofi-Synthelabo, 
Bagneux, France
In a large Phase III double-blind randomised clinical trial,
the CAPRIE study (clopidogrel versus aspirin in Patients
at Risk of Ischemic Events), two anti-platelet agents were
compared in secondary prevention of ischemic events
(myocardial infarction, ischemic stroke, vascular death)
in atherothrombotic patients. The study was not de-
signed to collect health economic parameters. OBJEC-
TIVES: we needed to assess the incremental cost-effec-
tiveness ratio of the new anti-platelet agent in the main
European countries and to test various hypotheses.
METHODS: Clinical outcomes: A Markov model de-
signed with several clinical states combined the rates of
all ischemic events (fatal and non fatal, primary and sub-
sequent) reported in the CAPRIE study. The rates of ad-
verse events were also taken into account. Survival data:
the remaining life expectancy of the patients who experi-
enced an event was not directly estimated from the CAP-
RIE study as the mean follow-up of the patients was only
two years. The survival estimates was approached by
identifying, in the Framingham study, cohorts of patients
similar to the CAPRIE patients. Resources use and costs:
decision trees about inpatient and outpatient manage-
ment of myocardial infarctions and ischemic strokes were
built from available data (literature, data base, expert
opinion) and were locally validated. RESULTS: The eco-
nomic model allowed to calculate the incremental cost-
effectiveness ratio of the new anti-platelet agent for the
basic scenario (CAPRIE study) and for other scenarios
(changes of the time horizon, considering that the com-
parator could not be the reference treatment for all the
patients in a real life situation, high risk patients analy-
sis). CONCLUSION: Because they are protocol driven,
the Phase III double-blind randomised clinical trials do
not usually reflect what would happen in the real life.
Modeling, which allows to perform simulations, could be
a way of correcting.
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MODELLING ISSUES: FIRST 
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Davies LM1, Lewis S2
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BACKGROUND: The development of an economic
model to assess antipsychotics for first episode schizo-
phrenia raised several issues: (i) clinical and economic ev-
idence relates to chronic schizophrenia; (ii) inconsistent
reporting of outcomes and adverse events; (iii) compari-
son of costs and outcomes across several interventions is
complicated by (a) an absence of head to head compari-
sons (b) intolerance or resistance to 3 plus antipsychotics.
OBJECTIVES: To design a decision analytic model to
evaluate the relative efficiency of antipsychotics. METH-
ODS: Two composite variables were defined to incorpo-
rate 23 efficacy and safety events: (i) acceptable treat-
ment (able/willing to continue allocated therapy, with/
without side effects or symptom control) (ii) unaccept-
able treatment (unacceptable side effects or symptom
control, non compliance). Utility values were defined for
each variable. Clinical data were extracted from system-
atic reviews separately for first episode and chronic
schizophrenia. Age specific resource use data were esti-
mated from national statistics to proxy first episode pa-
tients. Follow on therapy for people failing first therapy
was estimated by (i) specifying drug sequence; (ii) treat-
ing follow on therapy as a random event. Monte Carlo
simulation analysis was used to reduce complexity and
incorporate uncertainty. RESULTS: It was not possible
to identify consistent data for first episode patients only.
Interpretation of the specific treatment sequences was
complex with 32 possible combinations identified. There
were substantial differences within classes of antipsychot-
ics. The results were sensitive to: (i) specification of fol-
low on therapy (ii) distributional form applied to data.
CONCLUSIONS: The analysis highlighted the poor
quality and absence of relevant data. This could not be
dealt with by modelling. Current classifications of typical
and atypical antipsychotics may not be relevant.
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METHODOLOGY FOR IDENTIFYING PATIENTS 
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FRACTURES WITHIN A MANAGED 
CARE ENVIRONMENT
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